| SEC For   | rm 4   |     |  |          |  |                             |   |  |  |         |   |                    |  |   |   |   |   |                                       |
|---|--|-----|--|----------|--|-----------------------------|---|--|--|---------|---|--------------------|--|---|---|---|---|---------------------------------------|
| FORM 4  |  |     | UNITED STATES SECURITIES AND EXCHANGE COMMISS<br>Washington, D.C. 20549  |          |  |                             |   |  |  |         |   |                    |  |   |   |   |   |                                       |
| Section<br>obligat  | this box if no lo<br>n 16. Form 4 or<br>ions may conti<br>tion 1(b). |     | STATEMENT OF CHANGES IN BENEFICIAL OF<br>Filed pursuant to Section 16(a) of the Securities Exchange Act of<br>or Section 30(h) of the Investment Company Act of 1940 |          |  |                             |   |  |  |         | Act of 193  |                    | SHIP   | Estim   | OMB Number: 3235-0287   Estimated average burden    hours per response: 0.5 |   |   |                                       |
| 1. Name and Address of Reporting Person*<br>BARKER SAM L  |  |     |  |          | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Cyclacel Pharmaceuticals, Inc.</u> [ CYCC ] |                             |   |  |  |         |   |                    |  | eck all appli<br>X Directo  | cable)<br>or  | 10%   |   | Owner                                 |
| (Last) (First) (Middle)<br>C/O CYCLACEL PHARMACEUTICALS, INC.,<br>200 CONNELL DRIVE, SUITE 1500   |  |     |  |          | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/25/2020                                       |                             |   |  |  |         |   |                    |  | Officer (give title Other (specify below) below)  |   |   |   |                                       |
| (Street)<br>BERKEI<br>HEIGHT  | N  | J   | 07922  |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)   |                             |   |  |  |         |   |                    | Line   | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |   |   |   |                                       |
| (City) (State) (Zip)  |  |     |  |          |  |                             |   |  |  |         |   |                    |  |   |   |   |   |                                       |
|   |  | Tab | le I - Nor   | n-Deriva | ative Se   | ecurities Ac                | cqui                                    | red,   | Disp   | oosed o | of, o   | or Ben             | eficial  | ly Owned  | ł   |   |   |                                       |
| 1. Title of Security (Instr. 3)<br>Date<br>(Month/D   |  |     |  |          | 2A. Deemed<br>Execution Date<br>if any<br>(Month/Day/Yea   | e,   T                      | 3.<br>Transaction<br>Code (Instr.<br>8) |  | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3,<br>5) |         |   | (A) or<br>3, 4 and | ) or<br>4 and<br>5. Amount<br>Securities<br>Beneficial<br>Owned Fo<br>Reported |   | Form<br>(D) o   | vnership<br>n: Direct<br>r Indirect<br>nstr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)       |                                       |
|   |  |     |  |          |  |                             | -                                       | Code   | v  | Amount  |   | (A) or<br>(D)      | Price  | Transac<br>(Instr. 3  | tion(s)   |   |   | (1150.4)                              |
|   |  | 1   |  |          |  | urities Acq<br>ls, warrants |   |  |  |         |   |                    |  | Owned   |   |   |   |                                       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) 2. 3. Transaction<br>Date<br>Drice of<br>Derivative<br>Security (Month/Day/Ye<br>Security |  |     | Execution Date,<br>ar) if any  |          | 1.<br>Transaction<br>Code (Instr<br>3)   | nsaction of E               |   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |  |         | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Securit<br>(Instr. 3 and 4) |                    |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | ve derivative<br>Securities   |   | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4 | Beneficial<br>Ownership<br>(Instr. 4) |

Date Exercisable

06/25/2021

Expiration Date

06/25/2030

(right to buy) Explanation of Responses:

\$<mark>4.7</mark>

Stock Option

1. These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

## /s/ Sam L. Barker

Title

Common Stock

\*\* Signature of Reporting Person Date

\$0<sup>(1)</sup>

5,200

06/29/2020

D

Amount or Number of Shares

5,200

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/25/2020

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Code v

A

(A)

5,200

(D)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.